Tirzepatide for Weight Loss, Lowering HbA1c in Diabetes with Juan Frias, MD


Episode Highlights

1:10 - Key Takeaways from SURPASS-2

3:10 - Questions Yet to Be Answered in SURPASS Program

7:25 - Effects of 5 mg v. 10 mg v. 15 mg Terzepatide

12:30 - Advantages of GLP1/GIP v. GLP1s

Editor's Note: This episode of the Endocrine Outlook features a conversation with Juan Frias, MD, medical director of the National Research Institute. Frias is also the principal investigator of the SURPASS-2 trial which examined Eli Lilly’s Dual GLP1/GIP agonist tirzepatide against 1mg semaglutide for glucose control and weight loss in patients with type 2 diabetes.

This episode was recorded on March 4 after Lilly announced topline results of the trial in a press release. For more information on the SURPASS-2 trial, check out our related coverage.

Related Videos
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
© 2024 MJH Life Sciences

All rights reserved.